Pancreatic cancer has a timing problem. When the disease is found before it has spread beyond the pancreas, about 44% of patients are alive five years later. Across all stages, that figure falls to roughly 13%, largely because pancreatic cancer is so often discovered only after it has advanced.
What if a simple blood draw could help find it sooner?
A study published September 16, 2026, in Nature Medicine tested a new blood-based approach called PANXEON, short for PANcreatic cancer eXosome Early detectiON. Developed by researchers at City of Hope, the test looks for multiple biological signals associated with pancreatic cancer and uses artificial intelligence to combine them into a single risk score.
In an international study involving 1,785 people across four countries, PANXEON correctly identified stage I and II pancreatic cancers 87% of the time. Even more intriguing, it detected some high-risk precancerous changes before invasive cancer had developed.
The results don’t mean doctors suddenly have a routine blood test for pancreatic cancer. PANXEON remains experimental, and important questions about false positives and whether screening ultimately saves lives remain unanswered. But for a cancer in which finding the disease early can dramatically change a patient’s options, the results have attracted considerable attention.
Why pancreatic cancer is so hard to catch
Pancreatic ductal adenocarcinoma, or PDAC, carries an overall five-year survival rate of about 13%, the lowest among all major cancers. The disease is so lethal largely because of timing – it is usually discovered after it has spread, at which point surgery, the only treatment with genuine curative potential, is no longer an option for most patients.
According to the American Association for Cancer Research, the five-year survival rate for patients diagnosed at the earliest stages – before the cancer has spread from the pancreas – is 44.3%, compared to just 3.2% for those diagnosed with metastatic disease. That 40-point gap drives early-detection research.
The pancreas sits deep inside the abdomen and does not produce obvious symptoms when small tumors form. Current surveillance for people at increased risk relies primarily on MRI and endoscopic ultrasound, which can be costly, burdensome, and imperfect at detecting small pancreatic lesions. According to the American Cancer Society, people usually have no symptoms until the cancer has become very large or has already spread to other organs.
How PANXEON works
City of Hope researchers led the development of PANXEON, which is the first liquid biopsy to examine three established pancreatic cancer biomarkers – CA19-9, circulating microRNAs, and exosomal microRNAs – in each sample.
MicroRNAs are tiny molecules that help regulate how genes are switched on and off inside cells. When cancer develops, the pattern of microRNAs that a tumor releases into the bloodstream changes in detectable ways. Exosomes are small, membrane-wrapped sacs that cells continuously shed into the blood; tumor cells load their exosomes with specific microRNA signatures that reflect the cancer’s presence. PANXEON builds on a signature of 13 microRNAs – small noncoding RNA molecules that can reflect biological changes associated with cancer. Five of the markers circulate freely in plasma, while eight are carried within exosomes.
PANXEON tests a blood sample for circulating microRNAs, exosomal microRNAs, and a protein called CA19-9, then uses artificial intelligence to combine all three measurements into a single score that estimates a patient’s risk. CA19-9 is a protein long used to monitor cancer treatment response, but it cannot be used for screening on its own because elevated levels can result from benign conditions including pancreatitis and bile duct obstruction. By combining CA19-9 with the microRNA signature and running the combined signal through a machine-learning model, researchers aimed to produce a composite score more reliable than any single marker alone.
What the pancreatic cancer blood test study found
The microRNA signature alone achieved a sensitivity of 83.8% for early-stage PDAC in the testing cohort. Sensitivity, in this context, means the proportion of actual cancer cases the test correctly identified.
The full PANXEON score correctly identified stage I and stage II pancreatic cancers 87% of the time. The false-positive rate was approximately 3% in low-risk groups and 16% in high-risk groups. A false positive occurs when the test signals cancer in someone who does not actually have it. The 3% rate in low-risk patients is encouraging, though the 16% rate in high-risk populations is less clean – and that figure matters because high-risk individuals, those with family history, genetic mutations, pancreatic cysts, or chronic pancreatitis, are the population most likely to be tested first.
The finding that generated particular interest was the test’s performance on high-grade dysplasia – abnormal cell growth in the pancreas that has not yet become invasive cancer but carries a high risk of doing so. PANXEON detected high-grade dysplasia in 64.3% of high-risk pancreatic cyst cases. Catching cancer at that stage, before it becomes invasive, offers the closest thing oncology has to a genuine cure, and no blood test has reliably reached that territory before.
Researchers also tracked a smaller group of 19 patients through treatment. MicroRNA signature levels in these patients decreased during chemotherapy and after surgery, then rose again before confirmed disease recurrence, suggesting the test may eventually have utility for monitoring treatment response, not only for initial detection.
Who this test is actually for
Patients most likely to benefit include those with inherited risk, a family history of pancreatic cancer, pancreatic cysts, or chronic pancreatitis. The study was deliberately designed around high-risk populations rather than healthy general volunteers, which makes the results more clinically grounded but also means they cannot yet be generalized to average-risk adults.
Rather than replacing imaging or other diagnostic tests, PANXEON could help identify high-risk patients who should undergo further evaluation, according to Dr. Ajay Goel. A blood draw could serve as a first triage step, with imaging reserved for those who score positive – reducing the number of expensive, uncomfortable imaging procedures that people with elevated risk currently undergo on regular surveillance schedules.
The study enrolled 1,785 patients recruited at 12 institutions in the United States, Japan, Italy, and South Korea. Whether the test performs consistently across different ethnic backgrounds and healthcare settings is one of the questions its multi-country design was built to begin answering.
The limitations you need to know
PANXEON is experimental. It has not been approved by the FDA or any other regulatory body, and there is no timeline for when it might be.
The study does not prove that using PANXEON to screen people will save lives. That would require a different kind of trial – one that follows large populations over years to determine whether early detection through this test actually reduces deaths from pancreatic cancer. That evidence does not exist yet, and the researchers are explicit about it. The authors concluded that PANXEON may complement existing strategies for detecting early-stage PDAC and its precursors, and that the findings warrant confirmation in larger, prospectively followed high-risk populations.
The false-positive rate in high-risk groups is a particular concern. At 16%, roughly 1 in 6 high-risk patients who test positive would not actually have cancer. That means further imaging, biopsies, anxiety, and potential complications from unnecessary procedures. Any future deployment of the test would need to weigh that carefully.
The study also has not been validated in asymptomatic populations – people with no symptoms and no known elevated risk. That is the population where a true screening test would need to perform, and performance there remains unknown.
Dr. Ajay Goel, the study’s senior author, addressed both the promise and the remaining gaps directly. “Pancreatic cancer remains so deadly largely because we find it after the window for cure has begun to close,” he said in a statement reported by SciTechDaily. “For patients, these findings represent progress toward finding pancreatic cancer before symptoms appear and while more treatment options remain available.” The study authors also concluded that subsequent prospective studies in high-risk populations will be essential before the test’s accuracy estimates can be relied upon in clinical settings.
Promising, but not available yet
PANXEON isn’t ready for routine screening. It hasn’t been approved by the FDA or other regulatory bodies, and researchers still need prospective studies showing how well it performs when used to follow high-risk people over time. Most importantly, the current study cannot tell us whether detecting pancreatic cancer with PANXEON ultimately reduces deaths from the disease.
For people with a strong family history of pancreatic cancer, inherited genetic risk, pancreatic cysts, or chronic pancreatitis, the research may nevertheless be worth watching closely. These are the groups most likely to benefit from improved surveillance strategies if PANXEON continues to perform well in future studies. For now, people concerned about their risk should discuss established surveillance options with their healthcare provider rather than seeking out an experimental blood test.
For everyone else, the significance is less about getting tested tomorrow and more about what may be becoming possible. Pancreatic cancer has remained exceptionally difficult to detect during the window when treatment has the greatest chance of success. A blood test capable of reliably identifying that window would represent a major advance.
PANXEON hasn’t reached that point yet. But this study suggests researchers may be getting closer.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Woman’s Inoperable Brain Tumor Responds Rapidly to New Cancer Treatment